Furosemide effect on pregnancy hypertension

Furosemide versus Hydralazine for managing post partum hypertension in severe preeclampsia: A comparative study.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012082610674N1

Enrollment

100

Registered

2012-12-01

Start date

2008-05-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sever preeclampsia. Severe pre-eclampsia

Interventions

Intervention 1: In case group(Hydralazine) patients received Hydralazine10mg QID(Hydralazin hydrochloride 20 mg/ml

Abureyhan drug factory ) 5 days. Intervention 2: In control group (furosemide) patients received 10mg intramuscular furosemide BID for 5 day.(Furosemide20 mg/ml

Abureyhan Drug factory).

Treatment - Drugs

In case group(Hydralazine) patients received Hydralazine10mg QID(Hydralazin hydrochloride 20 mg/ml

Abureyhan drug factory ) 5 days.

In control group (furosemide) patients received 10mg intramuscular furosemide BID for 5 day.(Furosemide20 mg/ml

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Prim gravid patients; Sever preeclampsia Exclusion criteria: Chronic hypertension history; Renal disease; Mellitus diabetes; Smoking; Cardiovascular disease; Twin pregnancy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Hypertension. Timepoint: Q4h. Method of measurement: Mercury sphygmomanometer(mmgh).	—

Secondary

Measure	Time frame
Electrolyte imbalance. Timepoint: Daily. Method of measurement: Laboratory.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Nobakht

Dena Health Network

nobakht_f78@yahoo.com+98 74 1222 7092

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026